Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
企業コードPRPO
会社名Precipio Inc
上場日Jul 18, 2000
最高経営責任者「CEO」Mr. Ilan Danieli
従業員数54
証券種類Ordinary Share
決算期末Jul 18
本社所在地4 Science Park
都市NEW HAVEN
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号06511
電話番号12037877888
ウェブサイトhttps://www.precipiodx.com/
企業コードPRPO
上場日Jul 18, 2000
最高経営責任者「CEO」Mr. Ilan Danieli
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし